Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Mee...
April 02 2018 - 8:00AM
Business Wire
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology
company focused on the discovery, development and commercialization
of immunotherapy products, announces that The American Society of
Clinical Oncology has accepted the abstract titled “ADXS-PSA plus
pembrolizumab (pembro) in metastatic castration-resistant prostate
cancer (mCRPC)” for a poster discussion at their annual meeting to
be held June 1-5, 2018 in Chicago. The discussion will be presented
and lead by author and principle investigator of the study, Mark
Stein, MD, medical oncologist at Columbia University Medical
Center.
Title:
“ADXS-PSA plus pembrolizumab (pembro) in metastatic
castration-resistant prostate cancer (mCRPC)”
Abstract Number:
5019
Session:
Genitourinary (Prostate) Cancer
Date:
June 2, 2018 4:45 PM-6:00 PM
Presenter:
Mark Stein, MD
About ADXS—PSA
ADXS—PSA is currently being evaluated in a Phase 1/2 open-label,
multicenter dose determination and expansion trial in patients with
previously treated metastatic, castration-resistant prostate
cancer. The trial is being conducted in a clinical trial
collaboration and supply agreement with Merck & Co.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of proprietary
Lm-based antigen delivery products. These immunotherapies are based
on a platform technology that utilizes live attenuated Listeria
monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion
proteins. These Lm-based strains are believed to be a significant
advancement in immunotherapy as they integrate multiple functions
into a single immunotherapy and are designed to access and direct
antigen presenting cells to stimulate anti-tumor T cell immunity,
activate the immune system with the equivalent of multiple
adjuvants, and simultaneously reduce tumor protection in the tumor
microenvironment to enable the T cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and preclinical
development: HPV-associated cancers, neoantigen therapy, hotspot/
cancer antigens and prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop and commercialize the next generation of cancer
immunotherapies, and the safety and efficacy of Advaxis’
proprietary immunotherapies. These forward-looking statements are
subject to a number of risks including the risk factors set forth
from time to time in Advaxis’ SEC filings including, but not
limited to, its report on Form 10-K for the fiscal year ended
October 31, 2017, and on Form 10-Q for the quarter ended January
31, 2018, which are available at www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law. You are cautioned not to place undue reliance on
any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180402005291/en/
Advaxis, Inc.Noelle Heber, 609-250-7575Sr. Director Corporate
Communications and Government
AffairsHeber@advaxis.comorMedia:Stern Strategy GroupBrian
Hyland, 908-325-3891Bhyland@sternstrategy.comorRachel Auerbach,
908-325-3898Rauerbach@sternstrategy.comorInvestors:LHA
Investor RelationsMiriam Weber Miller,
212-838-3777mmiller@lhai.com
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024